Gilead Sciences acquired Forty Seven, Inc. for ~$4.9 billion, a transaction announced in March 2020.
Acquired the immuno-oncology company for $95.50 per share in cash to strengthen Gilead's oncology pipeline, gaining lead anti-CD47 antibody magrolimab in development for myelodysplastic syndrome, AML and DLBCL.
Acquired the immuno-oncology company for $95.50 per share in cash to strengthen Gilead's oncology pipeline, gaining lead anti-CD47 antibody magrolimab in development for myelodysplastic syndrome, AML and DLBCL.
Advisory firms were not disclosed for this transaction.